Amarin Corporation and Biologix FZco have announced that the Saudi Food and Drug Authority has approved VASCEPA® (icosapent ethyl) capsules as an adjunct to statin therapy in adult patients with elevated triglycerides levels who are at high-risk of cardiovascular events due to established cardiovascular disease or diabetes mellitus and at least one other risk factor for cardiovascular disease. This makes VASCEPA the first and only drug approved by SFDA for reducing CV risk beyond cholesterol lowering therapy in high-risk statin treated patients with elevated and high triglyceride levels.
VASCEPA is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management, committed to increasing scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Over 30% of adults over 18 years old in KSA are at risk of a CVD event, hence there is an urgent need to address CVD in KSA.